CA2461248C - Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a - Google Patents

Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a Download PDF

Info

Publication number: CA2461248C
Authority: CA; Canada
Prior art keywords: receptor; compound; ht2a; compounds; disease
Prior art date: 2003-12-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

CA 2461248

Other languages

English (en)

Other versions

CA2461248A1 (fr

Inventor

Erik Buntinx

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

PharmaNeuroBoost NV

Original Assignee

PharmaNeuroBoost NV

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-02

Filing date

2004-03-18

Publication date

2009-12-22

2003-12-02 Priority claimed from CA2451798A external-priority patent/CA2451798C/fr

2004-03-18 Application filed by PharmaNeuroBoost NV filed Critical PharmaNeuroBoost NV

2004-03-18 Priority to CA 2461248 priority Critical patent/CA2461248C/fr

2004-11-15 Priority to CA 2487529 priority patent/CA2487529A1/fr

2004-12-02 Priority to PCT/BE2004/000172 priority patent/WO2005053796A1/fr

2004-12-02 Priority to EP10159625A priority patent/EP2272514A1/fr

2004-12-02 Priority to ES04801138T priority patent/ES2343962T3/es

2004-12-02 Priority to RSP-2010/0323A priority patent/RS51331B/sr

2004-12-02 Priority to PL04801138T priority patent/PL1708790T3/pl

2004-12-02 Priority to HR20100376T priority patent/HRP20100376T1/hr

2004-12-02 Priority to AT04801138T priority patent/ATE464901T1/de

2004-12-02 Priority to CA002547639A priority patent/CA2547639A1/fr

2004-12-02 Priority to DE602004026781T priority patent/DE602004026781D1/de

2004-12-02 Priority to EP04801138A priority patent/EP1708790B1/fr

2004-12-02 Priority to SI200431439T priority patent/SI1708790T1/sl

2004-12-02 Priority to DK04801138.1T priority patent/DK1708790T3/da

2004-12-02 Priority to JP2006541759A priority patent/JP4571645B2/ja

2004-12-02 Priority to PT04801138T priority patent/PT1708790E/pt

2004-12-02 Priority to US10/580,962 priority patent/US8304431B2/en

2005-06-02 Publication of CA2461248A1 publication Critical patent/CA2461248A1/fr

2009-12-22 Publication of CA2461248C publication Critical patent/CA2461248C/fr

2009-12-22 Application granted granted Critical

2010-07-05 Priority to CY20101100611T priority patent/CY1111017T1/el

2010-09-30 Priority to US12/924,615 priority patent/US20110136865A1/en

2011-03-25 Priority to US13/065,638 priority patent/US20110207776A1/en

2024-03-18 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000004031 partial agonist Substances 0.000 title description 37
239000005557 antagonist Substances 0.000 title description 35
239000000556 agonist Substances 0.000 title description 9
230000001225 therapeutic effect Effects 0.000 claims abstract description 35
208000018737 Parkinson disease Diseases 0.000 claims abstract description 30
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
AXKPFOAXAHJUAG-UHFFFAOYSA-N pipamperone Chemical compound C1CC(C(=O)N)(N2CCCCC2)CCN1CCCC(=O)C1=CC=C(F)C=C1 AXKPFOAXAHJUAG-UHFFFAOYSA-N 0.000 claims description 50
239000004480 active ingredient Substances 0.000 claims description 49
229960002776 pipamperone Drugs 0.000 claims description 39
150000003839 salts Chemical class 0.000 claims description 27
229960004851 pergolide Drugs 0.000 claims description 22
238000002360 preparation method Methods 0.000 claims description 22
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims description 21
239000003814 drug Substances 0.000 claims description 19
150000001875 compounds Chemical class 0.000 abstract description 179
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 54
102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 abstract description 48
101710138091 5-hydroxytryptamine receptor 2A Proteins 0.000 abstract description 48
208000010877 cognitive disease Diseases 0.000 abstract description 47
208000015122 neurodegenerative disease Diseases 0.000 abstract description 42
239000000203 mixture Substances 0.000 abstract description 41
201000010099 disease Diseases 0.000 abstract description 36
230000004770 neurodegeneration Effects 0.000 abstract description 23
230000001270 agonistic effect Effects 0.000 abstract description 22
208000035475 disorder Diseases 0.000 abstract description 17
230000036961 partial effect Effects 0.000 abstract description 14
230000003042 antagnostic effect Effects 0.000 abstract description 10
102000005962 receptors Human genes 0.000 description 61
108020003175 receptors Proteins 0.000 description 61
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 48
238000011282 treatment Methods 0.000 description 48
108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 47
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 39
230000000694 effects Effects 0.000 description 34
229940125425 inverse agonist Drugs 0.000 description 29
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 26
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 26
102000015554 Dopamine receptor Human genes 0.000 description 26
108050004812 Dopamine receptor Proteins 0.000 description 26
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 26
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 25
229960004502 levodopa Drugs 0.000 description 25
239000002207 metabolite Substances 0.000 description 20
229960003638 dopamine Drugs 0.000 description 19
239000000651 prodrug Substances 0.000 description 19
229940002612 prodrug Drugs 0.000 description 19
102000010909 Monoamine Oxidase Human genes 0.000 description 17
108010062431 Monoamine oxidase Proteins 0.000 description 17
239000003136 dopamine receptor stimulating agent Substances 0.000 description 16
ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 16
239000003954 decarboxylase inhibitor Substances 0.000 description 15
239000000544 cholinesterase inhibitor Substances 0.000 description 14
208000024827 Alzheimer disease Diseases 0.000 description 13
239000003112 inhibitor Substances 0.000 description 13
IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 description 12
229940123736 Decarboxylase inhibitor Drugs 0.000 description 12
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 12
206010012289 Dementia Diseases 0.000 description 11
229940098778 Dopamine receptor agonist Drugs 0.000 description 11
230000008485 antagonism Effects 0.000 description 11
238000002648 combination therapy Methods 0.000 description 11
239000000126 substance Substances 0.000 description 11
238000002560 therapeutic procedure Methods 0.000 description 11
230000003190 augmentative effect Effects 0.000 description 10
229940122041 Cholinesterase inhibitor Drugs 0.000 description 9
208000020016 psychiatric disease Diseases 0.000 description 9
229960001653 citalopram Drugs 0.000 description 8
229960003980 galantamine Drugs 0.000 description 8
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 8
-1 olanzepine Chemical compound 0.000 description 8
208000024891 symptom Diseases 0.000 description 8
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 7
229940079593 drug Drugs 0.000 description 7
238000000034 method Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
208000031091 Amnestic disease Diseases 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
VGIGHGMPMUCLIQ-UHFFFAOYSA-N LSM-2183 Chemical compound C1=CC(F)=CC=C1N1CCN(CCCN2S(C=3C=CC=C4C=CC=C2C=34)(=O)=O)CC1 VGIGHGMPMUCLIQ-UHFFFAOYSA-N 0.000 description 6
229950002951 fananserin Drugs 0.000 description 6
230000002085 persistent effect Effects 0.000 description 6
239000000902 placebo Substances 0.000 description 6
229940068196 placebo Drugs 0.000 description 6
239000003826 tablet Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
239000002775 capsule Substances 0.000 description 5
210000003169 central nervous system Anatomy 0.000 description 5
238000003745 diagnosis Methods 0.000 description 5
239000002552 dosage form Substances 0.000 description 5
239000011159 matrix material Substances 0.000 description 5
210000002569 neuron Anatomy 0.000 description 5
229940076279 serotonin Drugs 0.000 description 5
239000002400 serotonin 2A antagonist Substances 0.000 description 5
239000012730 sustained-release form Substances 0.000 description 5
VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 description 4
OGJGQVFWEPNYSB-UHFFFAOYSA-N 3-[[4-(4-chlorophenyl)-1-piperazinyl]methyl]-1H-pyrrolo[2,3-b]pyridine Chemical compound C1=CC(Cl)=CC=C1N1CCN(CC=2C3=CC=CN=C3NC=2)CC1 OGJGQVFWEPNYSB-UHFFFAOYSA-N 0.000 description 4
PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 description 4
101150049660 DRD2 gene Proteins 0.000 description 4
102000003962 Dopamine D4 receptors Human genes 0.000 description 4
108090000357 Dopamine D4 receptors Proteins 0.000 description 4
239000000853 adhesive Substances 0.000 description 4
230000001070 adhesive effect Effects 0.000 description 4
230000008484 agonism Effects 0.000 description 4
NNAIYOXJNVGUOM-UHFFFAOYSA-N amperozide Chemical compound C1CN(C(=O)NCC)CCN1CCCC(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 NNAIYOXJNVGUOM-UHFFFAOYSA-N 0.000 description 4
229950000388 amperozide Drugs 0.000 description 4
229960005245 asenapine Drugs 0.000 description 4
210000004556 brain Anatomy 0.000 description 4
229960004170 clozapine Drugs 0.000 description 4
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 4
230000007850 degeneration Effects 0.000 description 4
ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
208000035474 group of disease Diseases 0.000 description 4
229960001057 paliperidone Drugs 0.000 description 4
239000006187 pill Substances 0.000 description 4
229960001534 risperidone Drugs 0.000 description 4
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 4
WNUQCGWXPNGORO-NRFANRHFSA-N sonepiprazole Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1CCN(CC[C@H]2C3=CC=CC=C3CCO2)CC1 WNUQCGWXPNGORO-NRFANRHFSA-N 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
239000000725 suspension Substances 0.000 description 4
238000013268 sustained release Methods 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
229960000607 ziprasidone Drugs 0.000 description 4
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 4
229960004496 zotepine Drugs 0.000 description 4
HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 4
GFNAQGUENCOUHQ-BOXHHOBZSA-N 4-[4-[2-[(1s)-3,4-dihydro-1h-isochromen-1-yl]ethyl]piperazin-1-yl]benzenesulfonamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(S(=O)(=O)N)=CC=C1N1CCN(CC[C@H]2C3=CC=CC=C3CCO2)CC1 GFNAQGUENCOUHQ-BOXHHOBZSA-N 0.000 description 3
QOYHHIBFXOOADH-UHFFFAOYSA-N 8-[4,4-bis(4-fluorophenyl)butyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 QOYHHIBFXOOADH-UHFFFAOYSA-N 0.000 description 3
ZFZPJDFBJFHYIV-UHFFFAOYSA-N 8-[4-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]butyl]-8-azaspiro[4.5]decane-7,9-dione Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2C3=CC=CC=C3SN=2)C(=O)CC21CCCC2 ZFZPJDFBJFHYIV-UHFFFAOYSA-N 0.000 description 3
KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 description 3
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 3
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
206010012218 Delirium Diseases 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
201000011240 Frontotemporal dementia Diseases 0.000 description 3
208000031886 HIV Infections Diseases 0.000 description 3
206010019196 Head injury Diseases 0.000 description 3
208000023105 Huntington disease Diseases 0.000 description 3
208000030990 Impulse-control disease Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
ZZQNEJILGNNOEP-UHFFFAOYSA-N Ocaperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)C=CC=C4C)=NOC2=C1 ZZQNEJILGNNOEP-UHFFFAOYSA-N 0.000 description 3
208000000609 Pick Disease of the Brain Diseases 0.000 description 3
208000024571 Pick disease Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 3
201000004810 Vascular dementia Diseases 0.000 description 3
229960003805 amantadine Drugs 0.000 description 3
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 3
229940127236 atypical antipsychotics Drugs 0.000 description 3
230000003542 behavioural effect Effects 0.000 description 3
BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 3
229960000911 benserazide Drugs 0.000 description 3
230000037396 body weight Effects 0.000 description 3
229960002802 bromocriptine Drugs 0.000 description 3
OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 3
229960004596 cabergoline Drugs 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000006071 cream Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
210000005064 dopaminergic neuron Anatomy 0.000 description 3
230000008482 dysregulation Effects 0.000 description 3
230000002996 emotional effect Effects 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
229960003532 fluspirilene Drugs 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
229960003587 lisuride Drugs 0.000 description 3
239000006210 lotion Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
230000015654 memory Effects 0.000 description 3
230000004060 metabolic process Effects 0.000 description 3
IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 description 3
208000027061 mild cognitive impairment Diseases 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
239000003176 neuroleptic agent Substances 0.000 description 3
229950010634 ocaperidone Drugs 0.000 description 3
239000002674 ointment Substances 0.000 description 3
229960003089 pramipexole Drugs 0.000 description 3
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 3
230000004044 response Effects 0.000 description 3
229960001879 ropinirole Drugs 0.000 description 3
UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 description 3
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
229960003678 selegiline hydrochloride Drugs 0.000 description 3
238000009097 single-agent therapy Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
210000003523 substantia nigra Anatomy 0.000 description 3
229950004554 tiospirone Drugs 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 2
ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 2
108060003345 Adrenergic Receptor Proteins 0.000 description 2
102000017910 Adrenergic receptor Human genes 0.000 description 2
102100029815 D(4) dopamine receptor Human genes 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Chemical class OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical class OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
208000026097 Factitious disease Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
101000865206 Homo sapiens D(4) dopamine receptor Proteins 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000016571 aggressive behavior Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000003693 atypical antipsychotic agent Substances 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
229960004205 carbidopa Drugs 0.000 description 2
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
229940111134 coxibs Drugs 0.000 description 2
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 2
230000006378 damage Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
229960003530 donepezil Drugs 0.000 description 2
229940052760 dopamine agonists Drugs 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
229960002866 duloxetine Drugs 0.000 description 2
239000007938 effervescent tablet Substances 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
239000008387 emulsifying waxe Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
239000003701 inert diluent Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000463 material Substances 0.000 description 2
BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
229960004640 memantine Drugs 0.000 description 2
229960000600 milnacipran Drugs 0.000 description 2
230000000966 norepinephrine reuptake Effects 0.000 description 2
230000037361 pathway Effects 0.000 description 2
230000001242 postsynaptic effect Effects 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
GWHQHAUAXRMMOT-MBANBULQSA-N rivastigmine tartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 GWHQHAUAXRMMOT-MBANBULQSA-N 0.000 description 2
230000000697 serotonin reuptake Effects 0.000 description 2
239000007909 solid dosage form Substances 0.000 description 2
239000000600 sorbitol Chemical class 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
229960001685 tacrine Drugs 0.000 description 2
YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
210000003478 temporal lobe Anatomy 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 2
229960004688 venlafaxine Drugs 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
LDXQLWNPGRANTO-GOSISDBHSA-N (9r)-7-[[3,5-bis(trifluoromethyl)phenyl]methyl]-9-methyl-5-(4-methylphenyl)-8,9,10,11-tetrahydro-[1,4]diazocino[2,1-g][1,7]naphthyridine-6,13-dione Chemical compound C([C@H](CN(CC=1C=C(C=C(C=1)C(F)(F)F)C(F)(F)F)C1=O)C)CN(C(C2=NC=CC=C22)=O)C1=C2C1=CC=C(C)C=C1 LDXQLWNPGRANTO-GOSISDBHSA-N 0.000 description 1
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
AENVFIFDTPYLLD-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindol-1-ol Chemical compound C1CCCC2C(O)NCC21 AENVFIFDTPYLLD-UHFFFAOYSA-N 0.000 description 1
WAOQONBSWFLFPE-VIFPVBQESA-N 3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1OC WAOQONBSWFLFPE-VIFPVBQESA-N 0.000 description 1
FKHYYOUFMJBLAF-UHFFFAOYSA-N 3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-n-methylpropan-1-amine Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 FKHYYOUFMJBLAF-UHFFFAOYSA-N 0.000 description 1
WIHSDUPAYPXRSA-UHFFFAOYSA-N 3-(3,3-dimethyl-1-phenyl-2h-inden-1-yl)-n-methylpropan-1-amine Chemical compound C1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 WIHSDUPAYPXRSA-UHFFFAOYSA-N 0.000 description 1
XLJWJFKYRFPJSD-LZQZEXGQSA-N 3-[2-[(1s,5r,6s)-6-(4-fluorophenyl)-3-azabicyclo[3.2.0]heptan-3-yl]ethyl]-1h-quinazoline-2,4-dione Chemical compound C1=CC(F)=CC=C1[C@@H]1[C@H]2CN(CCN3C(C4=CC=CC=C4NC3=O)=O)C[C@H]2C1 XLJWJFKYRFPJSD-LZQZEXGQSA-N 0.000 description 1
229940116892 5 Hydroxytryptamine 2B receptor antagonist Drugs 0.000 description 1
102000035038 5-HT1 receptors Human genes 0.000 description 1
108091005478 5-HT1 receptors Proteins 0.000 description 1
102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 1
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 1
102100024956 5-hydroxytryptamine receptor 2B Human genes 0.000 description 1
101710138092 5-hydroxytryptamine receptor 2B Proteins 0.000 description 1
102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 1
101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
102100040368 5-hydroxytryptamine receptor 6 Human genes 0.000 description 1
101710150235 5-hydroxytryptamine receptor 6 Proteins 0.000 description 1
AWFDCTXCTHGORH-HGHGUNKESA-N 6-[4-[(6ar,9r,10ar)-5-bromo-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline-9-carbonyl]piperazin-1-yl]-1-methylpyridin-2-one Chemical class O=C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4NC(Br)=C(C=34)C2)C1)C)N(CC1)CCN1C1=CC=CC(=O)N1C AWFDCTXCTHGORH-HGHGUNKESA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical class O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
208000000044 Amnesia Diseases 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
229920000945 Amylopectin Chemical class 0.000 description 1
206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
206010002820 Antisocial behaviour Diseases 0.000 description 1
208000019901 Anxiety disease Diseases 0.000 description 1
CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
208000012252 Attention deficit and disruptive behaviour disease Diseases 0.000 description 1
CYGODHVAJQTCBG-UHFFFAOYSA-N Bifeprunox Chemical compound C=12OC(=O)NC2=CC=CC=1N(CC1)CCN1CC(C=1)=CC=CC=1C1=CC=CC=C1 CYGODHVAJQTCBG-UHFFFAOYSA-N 0.000 description 1
XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
239000004255 Butylated hydroxyanisole Substances 0.000 description 1
102000004031 Carboxy-Lyases Human genes 0.000 description 1
108090000489 Carboxy-Lyases Proteins 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
102000003914 Cholinesterases Human genes 0.000 description 1
108090000322 Cholinesterases Proteins 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
229920002261 Corn starch Chemical class 0.000 description 1
102100020756 D(2) dopamine receptor Human genes 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 1
102000004980 Dopamine D2 Receptors Human genes 0.000 description 1
108090001111 Dopamine D2 Receptors Proteins 0.000 description 1
229940121891 Dopamine receptor antagonist Drugs 0.000 description 1
101150043870 Drd4 gene Proteins 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
208000005171 Dysmenorrhea Diseases 0.000 description 1
206010013935 Dysmenorrhoea Diseases 0.000 description 1
102100029503 E3 ubiquitin-protein ligase TRIM32 Human genes 0.000 description 1
208000030814 Eating disease Diseases 0.000 description 1
208000019454 Feeding and Eating disease Diseases 0.000 description 1
PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 description 1
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
101150104779 HTR2A gene Proteins 0.000 description 1
208000004547 Hallucinations Diseases 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
102100032509 Histamine H1 receptor Human genes 0.000 description 1
101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 description 1
101000634982 Homo sapiens E3 ubiquitin-protein ligase TRIM32 Proteins 0.000 description 1
101001016841 Homo sapiens Histamine H1 receptor Proteins 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Chemical class 0.000 description 1
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
208000026139 Memory disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
208000019022 Mood disease Diseases 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
208000011644 Neurologic Gait disease Diseases 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
102000001675 Parvalbumin Human genes 0.000 description 1
108060005874 Parvalbumin Proteins 0.000 description 1
RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
206010036618 Premenstrual syndrome Diseases 0.000 description 1
208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
208000027520 Somatoform disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Chemical class 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical class O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 description 1
KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
206010044565 Tremor Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
208000012826 adjustment disease Diseases 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000001800 adrenalinergic effect Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
229960003036 amisulpride Drugs 0.000 description 1
NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 1
229940025084 amphetamine Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
239000000935 antidepressant agent Substances 0.000 description 1
229940005513 antidepressants Drugs 0.000 description 1
229960004372 aripiprazole Drugs 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 description 1
229960002430 atomoxetine Drugs 0.000 description 1
238000001266 bandaging Methods 0.000 description 1
210000004227 basal ganglia Anatomy 0.000 description 1
230000006399 behavior Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
229950002871 blonanserin Drugs 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
210000000133 brain stem Anatomy 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
229940043253 butylated hydroxyanisole Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
229960000590 celecoxib Drugs 0.000 description 1
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
239000007910 chewable tablet Substances 0.000 description 1
229960001076 chlorpromazine Drugs 0.000 description 1
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
229940048961 cholinesterase Drugs 0.000 description 1
VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical class C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 1
150000008371 chromenes Chemical class 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
VKQDZNZTPGLGFD-UHFFFAOYSA-N ciclazindol Chemical compound C12=NCCCN2C2=CC=CC=C2C1(O)C1=CC=CC(Cl)=C1 VKQDZNZTPGLGFD-UHFFFAOYSA-N 0.000 description 1
229950009468 ciclazindol Drugs 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
230000003920 cognitive function Effects 0.000 description 1
229940000425 combination drug Drugs 0.000 description 1
229940124301 concurrent medication Drugs 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
239000008120 corn starch Chemical class 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
229960003314 deracoxib Drugs 0.000 description 1
WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
235000013681 dietary sucrose Nutrition 0.000 description 1
235000014632 disordered eating Nutrition 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
208000018459 dissociative disease Diseases 0.000 description 1
239000003210 dopamine receptor blocking agent Substances 0.000 description 1
229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 description 1
229940000406 drug candidate Drugs 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
VAIOZOCLKVMIMN-PRJWTAEASA-N eplivanserin Chemical compound C=1C=CC=C(F)C=1\C(=N/OCCN(C)C)\C=C\C1=CC=C(O)C=C1 VAIOZOCLKVMIMN-PRJWTAEASA-N 0.000 description 1
229950000789 eplivanserin Drugs 0.000 description 1
229960004945 etoricoxib Drugs 0.000 description 1
MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
230000021824 exploration behavior Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960002464 fluoxetine Drugs 0.000 description 1
XSOUHEXVEOQRKJ-IUCAKERBSA-N fluparoxan Chemical compound O1[C@H]2CNC[C@@H]2OC2=C1C=CC=C2F XSOUHEXVEOQRKJ-IUCAKERBSA-N 0.000 description 1
229950006702 fluparoxan Drugs 0.000 description 1
229960002690 fluphenazine Drugs 0.000 description 1
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
229960004038 fluvoxamine Drugs 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000001905 globus pallidus Anatomy 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229960003878 haloperidol Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
230000005802 health problem Effects 0.000 description 1
230000000971 hippocampal effect Effects 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
229960003162 iloperidone Drugs 0.000 description 1
XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011221 initial treatment Methods 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
210000001153 interneuron Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000003874 inverse correlation nuclear magnetic resonance spectroscopy Methods 0.000 description 1
XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000002372 labelling Methods 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
MJRPHRMGEKCADU-JVLSTEMRSA-N lortalamine Chemical compound C12=CC(Cl)=CC=C2O[C@]23CCN(C)C[C@@H]2[C@H]1CC(=O)N3 MJRPHRMGEKCADU-JVLSTEMRSA-N 0.000 description 1
229950004863 lortalamine Drugs 0.000 description 1
KHPKQFYUPIUARC-UHFFFAOYSA-N lumiracoxib Chemical compound OC(=O)CC1=CC(C)=CC=C1NC1=C(F)C=CC=C1Cl KHPKQFYUPIUARC-UHFFFAOYSA-N 0.000 description 1
229960001432 lurasidone Drugs 0.000 description 1
PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
208000024714 major depressive disease Diseases 0.000 description 1
238000007726 management method Methods 0.000 description 1
239000000594 mannitol Chemical class 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
229960001929 meloxicam Drugs 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000006984 memory degeneration Effects 0.000 description 1
208000023060 memory loss Diseases 0.000 description 1
230000007334 memory performance Effects 0.000 description 1
230000003340 mental effect Effects 0.000 description 1
229960000300 mesoridazine Drugs 0.000 description 1
SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000011859 microparticle Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
YBCBOXOAJAQPQU-UHFFFAOYSA-N n-(2-cyclohexyloxy-3-nitrophenyl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CC([N+]([O-])=O)=C1OC1CCCCC1 YBCBOXOAJAQPQU-UHFFFAOYSA-N 0.000 description 1
NXLUTEDAEFXMQR-BJKOFHAPSA-N n-[(2r,4s)-1-[3,5-bis(trifluoromethyl)benzoyl]-2-[(4-chlorophenyl)methyl]piperidin-4-yl]quinoline-4-carboxamide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C(=O)N2[C@@H](C[C@H](CC2)NC(=O)C=2C3=CC=CC=C3N=CC=2)CC=2C=CC(Cl)=CC=2)=C1 NXLUTEDAEFXMQR-BJKOFHAPSA-N 0.000 description 1
239000002105 nanoparticle Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229960001800 nefazodone Drugs 0.000 description 1
VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
230000001722 neurochemical effect Effects 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
210000002682 neurofibrillary tangle Anatomy 0.000 description 1
239000002742 neurokinin 1 receptor antagonist Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
230000008284 neuronal mechanism Effects 0.000 description 1
231100000189 neurotoxic Toxicity 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
229960001073 nomifensine Drugs 0.000 description 1
XXPANQJNYNUNES-UHFFFAOYSA-N nomifensine Chemical compound C12=CC=CC(N)=C2CN(C)CC1C1=CC=CC=C1 XXPANQJNYNUNES-UHFFFAOYSA-N 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
229960005017 olanzapine Drugs 0.000 description 1
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
230000008520 organization Effects 0.000 description 1
DZOJBGLFWINFBF-UMSFTDKQSA-N osanetant Chemical compound C([C@](C1)(CCCN2CCC(CC2)(N(C(C)=O)C)C=2C=CC=CC=2)C=2C=C(Cl)C(Cl)=CC=2)CCN1C(=O)C1=CC=CC=C1 DZOJBGLFWINFBF-UMSFTDKQSA-N 0.000 description 1
229950009875 osanetant Drugs 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
229960004662 parecoxib Drugs 0.000 description 1
TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 description 1
229960002296 paroxetine Drugs 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000002304 perfume Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
229950004193 perospirone Drugs 0.000 description 1
GTAIPSDXDDTGBZ-OYRHEFFESA-N perospirone Chemical compound C1=CC=C2C(N3CCN(CC3)CCCCN3C(=O)[C@@H]4CCCC[C@@H]4C3=O)=NSCC2=C1 GTAIPSDXDDTGBZ-OYRHEFFESA-N 0.000 description 1
229960000762 perphenazine Drugs 0.000 description 1
208000022821 personality disease Diseases 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
AMJPIGOYWBNJLP-UHFFFAOYSA-N pirandamine Chemical compound C1C2=CC=CC=C2C2=C1C(CCN(C)C)(C)OCC2 AMJPIGOYWBNJLP-UHFFFAOYSA-N 0.000 description 1
229950007239 pirandamine Drugs 0.000 description 1
229960002702 piroxicam Drugs 0.000 description 1
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
229940068918 polyethylene glycol 400 Drugs 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920001592 potato starch Chemical class 0.000 description 1
230000003518 presynaptic effect Effects 0.000 description 1
230000006416 presynaptic localization Effects 0.000 description 1
210000000063 presynaptic terminal Anatomy 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
229960004063 propylene glycol Drugs 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
229940001470 psychoactive drug Drugs 0.000 description 1
239000004089 psychotropic agent Substances 0.000 description 1
239000008213 purified water Substances 0.000 description 1
229960004431 quetiapine Drugs 0.000 description 1
URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 1
229950001518 raclopride Drugs 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
229960003770 reboxetine Drugs 0.000 description 1
CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
239000002469 receptor inverse agonist Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960000371 rofecoxib Drugs 0.000 description 1
RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 description 1
HKFMQJUJWSFOLY-OAQYLSRUSA-N sarizotan Chemical compound C1=CC(F)=CC=C1C1=CN=CC(CNC[C@@H]2OC3=CC=CC=C3CC2)=C1 HKFMQJUJWSFOLY-OAQYLSRUSA-N 0.000 description 1
229950007903 sarizotan Drugs 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
230000000698 schizophrenic effect Effects 0.000 description 1
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
230000008313 sensitization Effects 0.000 description 1
229960000652 sertindole Drugs 0.000 description 1
GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 1
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
229960002073 sertraline Drugs 0.000 description 1
208000012201 sexual and gender identity disease Diseases 0.000 description 1
229940001089 sinemet Drugs 0.000 description 1
208000019116 sleep disease Diseases 0.000 description 1
229950001013 sonepiprazole Drugs 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000006190 sub-lingual tablet Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
229960004793 sucrose Drugs 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000007939 sustained release tablet Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
LJBBMCNHIUJBDU-UHFFFAOYSA-N talopram Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 LJBBMCNHIUJBDU-UHFFFAOYSA-N 0.000 description 1
229950007352 talopram Drugs 0.000 description 1
229950002139 talsupram Drugs 0.000 description 1
BRPOADLGOFPKKJ-UHFFFAOYSA-N tandamine Chemical compound C12=CC=CC=C2N(CC)C2=C1CCSC2(C)CCN(C)C BRPOADLGOFPKKJ-UHFFFAOYSA-N 0.000 description 1
229950006964 tandamine Drugs 0.000 description 1
229960002784 thioridazine Drugs 0.000 description 1
MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
229940100640 transdermal system Drugs 0.000 description 1
229960003991 trazodone Drugs 0.000 description 1
PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
229960002324 trifluoperazine Drugs 0.000 description 1
ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 1
229960002004 valdecoxib Drugs 0.000 description 1
LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000007497 verbal memory Effects 0.000 description 1
229960001255 viloxazine Drugs 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CA 2461248 2003-12-02 2004-03-18 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a Expired - Fee Related CA2461248C (fr)

Priority Applications (20)

Application Number	Priority Date	Filing Date	Title
CA 2461248 CA2461248C (fr)	2003-12-02	2004-03-18	Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a
CA 2487529 CA2487529A1 (fr)	2003-12-02	2004-11-15	Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a
DE602004026781T DE602004026781D1 (de)	2003-12-02	2004-12-02	Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonist
DK04801138.1T DK1708790T3 (da)	2003-12-02	2004-12-02	Anvendelse af pipamperon af en D2-receptorantagonist eller serotonin/dopaminantagonist til behandling af psykotiske sygdomme
ES04801138T ES2343962T3 (es)	2003-12-02	2004-12-02	Uso de pipamperona y un antagonista de receptores d2 o un antagonista de serotonina/dopamina para el tratamiento de trastornos psicoticos.
RSP-2010/0323A RS51331B (sr)	2003-12-02	2004-12-02	Upotreba pipamperona i antagonista d2-receptora ili serotoninsko/dopaminskih antagonista za lečenje psihotičkih poremećaja
PL04801138T PL1708790T3 (pl)	2003-12-02	2004-12-02	Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
HR20100376T HRP20100376T1 (hr)	2003-12-02	2004-12-02	Uporaba pipamperona i antagonista d2-receptora ili antagonista serotonin/dopamina za liječenje psihotičnih poremećaja
AT04801138T ATE464901T1 (de)	2003-12-02	2004-12-02	Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonisten zur behandlung von psychotischen störungen
CA002547639A CA2547639A1 (fr)	2003-12-02	2004-12-02	Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a,
PCT/BE2004/000172 WO2005053796A1 (fr)	2003-12-02	2004-12-02	Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a,
EP04801138A EP1708790B1 (fr)	2003-12-02	2004-12-02	Utilisation de pipamperone et d'un antagoniste des recepteurs d2 ou d'un antagoniste a la dopamine et a la serotonine pour le traitement de troubles psychotiques
SI200431439T SI1708790T1 (sl)	2003-12-02	2004-12-02	Uporaba pipamerona in d receptorskega antagonista kot serotonin dopamin antagonista za zdravljenjepsihičnih nepravilnosti
EP10159625A EP2272514A1 (fr)	2003-12-02	2004-12-02	Utilisation d'une faible dose de pipamperone et d'un deuxième agent actif dans le traitement des maladies neurodégénératives
JP2006541759A JP4571645B2 (ja)	2003-12-02	2004-12-02	Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
PT04801138T PT1708790E (pt)	2003-12-02	2004-12-02	Utilizaão de pipamperona e de um antagonista dos receptores d2 ou de um antagonista da dopamina e da serotonina para o tratamento de transtornos psicëticos
US10/580,962 US8304431B2 (en)	2003-12-02	2004-12-02	Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CY20101100611T CY1111017T1 (el)	2003-12-02	2010-07-05	Χρηση πιπαμπερονης και ενος ανταγωνιστη d-2 υποδοχεα ή ανταγωνιστη σεροτονινης/ντοπαμινης για την θεραπεια ψυχωτικων διαταραχων
US12/924,615 US20110136865A1 (en)	2003-12-02	2010-09-30	Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US13/065,638 US20110207776A1 (en)	2003-12-02	2011-03-25	Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
CA2451798A CA2451798C (fr)	2003-12-02	2003-12-02	Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a
CA2,451,798		2003-12-02
EP04447001		2004-01-05
EP04447001.1		2004-01-05
CA 2461248 CA2461248C (fr)	2003-12-02	2004-03-18	Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a

Publications (2)

Publication Number	Publication Date
CA2461248A1 CA2461248A1 (fr)	2005-06-02
CA2461248C true CA2461248C (fr)	2009-12-22

Family

ID=34623380

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2461248 Expired - Fee Related CA2461248C (fr)	2003-12-02	2004-03-18	Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a

Country Status (1)

Country	Link
CA (1)	CA2461248C (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7855195B2 (en)	2003-12-02	2010-12-21	Pharmaneuroboost N.V.	Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1708790B1 (fr)	2003-12-02	2010-04-21	PharmaNeuroBoost N.V.	Utilisation de pipamperone et d'un antagoniste des recepteurs d2 ou d'un antagoniste a la dopamine et a la serotonine pour le traitement de troubles psychotiques
US7884096B2 (en)	2003-12-02	2011-02-08	Pharmaneuroboost N.V.	Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2021139874A1 (fr) *	2020-01-06	2021-07-15	Anima	Prévention et traitement de troubles cognitifs

2004
- 2004-03-18 CA CA 2461248 patent/CA2461248C/fr not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2461248A1 (fr)	2005-06-02

Legal Events

Date	Code	Title	Description
2004-03-18	EEER	Examination request
2014-04-29	MKLA	Lapsed	Effective date: 20140318

Publication	Publication Date	Title
US20050119249A1 (en)	2005-06-02	Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US8304431B2 (en)	2012-11-06	Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050203130A1 (en)	2005-09-15	Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7855195B2 (en)	2010-12-21	Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20110172251A1 (en)	2011-07-14	Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
DE60200492T2 (de)	2004-09-16	Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen
US9732059B2 (en)	2017-08-15	Methods of use of cyclic amide derivatives to treat schizophrenia
EP1576985A1 (fr)	2005-09-21	Utilisation d'antagonistes, d'agonistes partiels ou d'agonistes inverses des recepturs D4 et 5-HT2A
JP4571485B2 (ja)	2010-10-27	Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
US20060211686A1 (en)	2006-09-21	Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions
US20250179044A1 (en)	2025-06-05	Methods of use of cyclic amide derivatives to treat schizophrenia
US20120010242A1 (en)	2012-01-12	Low dose pipamperone in treating mood disorders
EA015566B1 (ru)	2011-10-31	Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая
EP1547650A1 (fr)	2005-06-29	Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des récepteurs D4 et 5-HT2A
EP2236138A1 (fr)	2010-10-06	Pipampèrone faible dose pour le traitement des troubles de l`anxiété et de l`humeur
CA2461248C (fr)	2009-12-22	Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a
EP2236157A1 (fr)	2010-10-06	Pipampérone et un agent ultérieur pour le traitement des troubles de l'humeur et de l'anxiété
WO2006000222A2 (fr)	2006-01-05	Combinaison d'un antipsychotique et d'un inhibiteur de type 1 transporteur de glycine pour le traitement de la schizophrenie
JP4571645B2 (ja)	2010-10-27	Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
AU6378199A (en)	2000-04-03	A new composition
CA2451798C (fr)	2010-11-02	Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a
WO2012072665A1 (fr)	2012-06-07	Compositions comprenant de la pipampérone et des antagonistes/inhibiteurs de la recapture de la sérotonine
AU2003263357A1 (en)	2004-04-30	Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines
JP2002524507A (ja)	2002-08-06	新規組成物
RS51331B (sr)	2011-02-28	Upotreba pipamperona i antagonista d2-receptora ili serotoninsko/dopaminskih antagonista za lečenje psihotičkih poremećaja